Press Releases

The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.

Shed Introduces Low-Dose Naltrexone (LDN) to Support Metabolism, Chronic Pain, and Autoimmune Health, Enhancing Weight-Loss Solutions

Shed, a telehealth clinic specializing in weight loss, is excited to announce Low-Dose Naltrexone (LDN), an innovative, therapeutic solution for individuals managing chronic pain, autoimmune diseases, and metabolic health challenges. LDN works by naturally balancing the immune system, reducing inflammation, and providing pain relief, offering a much-needed alternative for patients seeking to address the root causes of their conditions.

Sucraid® (sacrosidase) Oral Solution, the only FDA-approved therapy to treat CSID (Congenital Sucrase-Isomaltase Deficiency), is now offering a free 4-day trial

QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid® (sacrosidase) Oral Solution has been shown to be 81% effective in treating patients with Congenital Sucrase-Isomaltase Deficiency (CSID) when used appropriately.1 Eligible patients can now try Sucraid® for free with a 4-day trial offer through their medical provider.

Sebela Women's Health Inc. Announces FDA Approval of MIUDELLA®, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years

Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA® (copper intrauterine system) for the prevention of pregnancy in females of reproductive potential for up to three years. MIUDELLA is a next-generation, hormone-free, low-dose copper intrauterine device or IUD, the first to be approved by the FDA in the United States in over 40 years.

Abdelghani (Abdel) Omari, Chief Financial Officer, Avanzanite Bioscience

Avanzanite Bioscience has appointed a Chief Financial Officer

Avanzanite Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company advancing life-changing medicines for rare disease patients across Europe, announces the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO).

Vertex announces FDA approval of JOURNAVX™ (suzetrigine), a first-in-class treatment for adults with moderate-to-severe acute pain

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.

Beckman Coulter’s Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test.

Beckman Coulter receives FDA breakthrough device designation for a blood test for Alzheimer's disease

Beckman Coulter Diagnostics, a global leader in clinical diagnostics, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter's Access p‑Tau217/β-Amyloid 1-42 plasma ratio. This blood test is designed to aid healthcare providers identify patients with amyloid pathology associated with Alzheimer's disease.

Young Pharmaceuticals reveals an exclusive partnership with LAC2βiome for U.S. distribution

Young Pharmaceuticals, Inc., a leading provider of physician-dispensed skincare products, announces an exclusive distribution agreement with LAC2βiome S.r.l., a maker of microbial based product solutions in Milan, Italy.

The next evolution of the V-OVS® syringe closure system is introduced by Vetter

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.

CELL HANDLER™ 2 to Debut by Yamaha Motor

Yamaha Motor Co., Ltd. (Tokyo: 7272) announced that it will exhibit the CELL HANDLER™ 2, a cell picking and imaging system, at marking the product's first overseas exhibition.

SN BioScience receives FDA IND clearance to propel SNB-101 into Phase 2

SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as an orphan drug for small cell lung cancer in 2023 and its Fast Track designation in 2024.

Latest Press Releases